Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter


MD Becker Partners 3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference

On Thursday, October 4, 2012, MD Becker Partners will host its Third Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine in New York City.  This unique, single-day conference event unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.  
To view the keynote address and select plenary sessions and panel discussions from last year's event, please visit the firm's new YouTube page at: www.youtube.com/mdbeckerpartners
A direct link to last year's keynote address by Axel Hoos, M.D., Ph.D., Co-Chairman of the Cancer Immunotherapy Consortium, is displayed below:

MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry. We also work with venture capitalists, institutional investors, and others that provide capital to these companies. As a strategic advisor and partner, we provide a full range of services to help our clients increase visibility, unlock stakeholder value and access resources to grow their business. To accomplish this, we integrate relations, strategy, and operational capabilities and apply them to carefully conceived and expertly enacted tactics. Visit our website to learn more at www.mdbpartners.com.

PrintView Printer Friendly Version

EmailEmail Article to Friend

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability ($SNGX) | Main | Human Genome ($HGSI) RBC says current GSK bid for Human Genome undervalues sum of parts over long-run ($14.64) »